Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?. (3rd August 2018)

• Record Type: Journal Article
• Authors: Schiavi, Michele Carlo; Sciuga, Valentina; Giannini, Andrea; Vena, Flaminia; D'oria, Ottavia; Prata, Giovanni; Di Tucci, Chiara; Savone, Delia; Aleksa, Natalia; Capone, Carmela; Di Mascio, Daniele; Meggiorini, Maria Letizia; Monti, Marco; Zullo, Marzio Angelo; Muzii, Ludovico; Benedetti Panici, Pierluigi
• Is Part Of: Gynecological endocrinology. Volume 34:Number 8(2018)
• Page Start: 666
• Page End: 669
• Publication Date: 2018-08-03
• Subjects: Vulvovaginal atrophy -- overactive bladder syndrome -- ospemifene -- sexual function -- quality of life; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2018.1441398
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60 mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks. Patients completed the OAB-Q SF, FSFI, FSDS, and SF-36 questionnaires. The patient's satisfaction was also calculated. After 12 weeks, the reduction of urinary symptoms was observed. The OAB-Q symptoms, OAB-Q (HRQL) score were (55.34 ± 13.54 vs. 23.22 ± 9.76; p < .0001) and (22.45 ± 9.78 vs. 70.56 ± 15.49; p < .0001), before and after treatment. SF-36 questionnaire showed a significant improvement ( p < .0001). VHI score increased and the women who regularly practice sexual activity increased after treatment. The total FSFI score increased significantly and the FSDS score changed after 12 weeks ( p < .0001). The PGI-I after 12 weeks showed a total success rate of 90.5%. Ospemifene is an effective potential therapy for postmenopausal women with VVA affected by OAB or UUI improving sexual function and quality of life.